# Eli Lilly and Company (LLY) — Q4-2022 Earnings Results

**Report date:** 2023-02-02 (before market open)  
**Sector:** Health Care / Pharmaceuticals  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/LLY/earnings/Q4-2022

## Post-Earnings Brief

### Headline

Eli Lilly Beats on EPS, Stock Down 3.46%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.09 | N/A | +14.27% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Management remains focused on advancing their pipeline and addressing market dynamics. They emphasized the importance of their product portfolio.

**Key quotes:**

> Management highlighted strong performance in key therapeutic areas.

> They expressed commitment to ongoing innovation despite market challenges.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Eli Lilly's earnings report showed a positive surprise in EPS, indicating better-than-expected profitability. However, the stock fell by 3.46%, likely due to a lack of revenue details and forward guidance, which may have left investors uncertain about future performance. The cautious tone from management suggests they are aware of challenges ahead but remain focused on their strategic goals.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/LLY/earnings/Q4-2022_